

Chapter 6

The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential

GMJ Bos, DTS Rijkers, HPJ Willems, M den Heijer, S Béguin, WBJ Gerrits, HC Hemker

Adapted from:

Thrombosis and Haemostasis 1999;81:467–468

Introduction

Several case control studies and a recent prospective study showed that in patients with (idiopathic) venous thrombosis mild hyperhomocysteinemia (HH) can be observed 2-3 times more frequently than in controls¹⁻³. The pathogenetic explanation for this clinical observation is not known. In principal a thrombotic tendency can originate in the blood, in the vessel wall or at the level of thrombocytes. The question that we wanted to answer was whether the thrombotic tendency that might accompany HH is caused by a higher capacity of these persons to generate thrombin. The plasmatic component of a thrombotic tendency might be reflected in the capacity of the platelet poor plasma to generate thrombin. This capacity can be assessed by measuring the endogenous thrombin potential (ETP), i.e. the surface under the thrombin generation curve⁴⁻⁶. It has been shown that the ETP is significantly increased in such plasma based thrombotic tendencies as deficiencies in AT and mutated Factor V Leiden^{6,7}. The influence of exogenous activated protein C (APC)^{8,9} and exogenous thrombomodulin (TM)^{10,11} on the inhibition of the ETP was recently shown and was used to screen for a deficient protein C pathway. In order to see whether a plasmatic component can explain the thrombotic tendency in HH, we tested the possible relationship between the concentration of homocysteine (tHcy) and thrombin generation in a group of healthy controls, without any venous thrombotic events in the past.

Methods

Blood samples of 30 persons with elevated levels of tHcy (>18 µmol/l; mean: 22.7 µmol/l) were selected. Samples of 30 persons matched for age and sex with normal tHcy levels (mean: 14.2 µmol/l) were used as controls (for details on study group selection see ref. 12). Homocysteine values of >18 µmol/l are clearly associated with increased risk for venous thrombosis^{13,14}. We deliberately did not include patients with venous thrombosis in the past, so as to exclude the possibility of plasma changes caused by the thrombotic process itself. We determined the ETP under standard conditions (extrinsically and intrinsically) and in the presence of exogenous APC or TM. The assay method for determining the ETP is based on the continuous monitoring of thrombin formation using a slow reacting thrombin substrate essentially as described earlier⁴ which method has been adapted for high throughput screening on a Cobas centrifugal analyzer⁶. The anticoagulant response towards TM was expressed as the thrombomodulin ratio (TMR); TMR: (ETP+TM/ETP-TM)pool/ (ETP+TM /ETP-TM)sample. The anticoagulant response towards APC was

expressed as the APC sensitivity ratio (APC-sr): $(a2M-Ila+APC/a2M-Ila-APC)_{sample} / (a2M-Ila+APC/a2M-Ila-APC)_{pool}$.

Results

The data on the subjects under study are given in Table 6.1. There was a narrow association between the intrinsic and extrinsic ETP. The Pearson correlation is 0.876 ($p=0.001$) (data not shown). However, for both intrinsic ETP and extrinsic ETP we found no correlation with tHcy. Comparing the two different groups no difference was present between those with normal tHcy levels and those with elevated tHcy levels. The intrinsic ETP in those with elevated tHcy was 412 (99% of reference plasma) similar to those with normal tHcy. The extrinsic ETP was 100% of reference plasma in those with elevated tHcy and 106% of reference plasma in those with normal tHcy. There was clearly no association between tHcy and TMR (coefficient is 0.04; $p=0.74$) and no difference between the group with high tHcy and those with normal tHcy was observed. Also no difference in APC-sr ratio could be observed between those with high and normal tHcy levels.

Table 6.1 Homocysteine and ETP values of persons under study.

| | normal tHcy | high tHcy | p-value |
|--------------------|-------------------|-------------------|---------|
| tHcy mean (μmol/l) | 14.2 | 22.7 | |
| tHcy range | 8.4 – 16.5 | 18.0 – 49.8 | |
| Mean age (range) | 55.2 (23 - 82) | 55.1 (23 - 80) | |
| Male (N) | 15 | 15 | |
| Female (N) | 15 | 15 | |
| ETP intrinsic | 412 +/- 72 nM.Min | 412 +/- 66 nM.Min | 0.6 |
| ETP extrinsic | 419 +/- 65 nM.Min | 395 +/- 56 nM.Min | 0.15 |
| APC-sr | 1.37 +/- 0.33 | 1.41 +/- 0.51 | 0.75 |
| TMR | 0.83 +/- 0.15 | 0.86 +/- 0.18 | 0.37 |

Discussion

Since no association of the ETP and homocysteine levels was observed and no influence of homocysteine on the ETP in the presence of APC or TM, our data do not support the idea that HH acts via the plasmatic coagulation system.

Others suggested a role for factor V or activated protein C. In addition an enhanced turnover or diminished formation of thrombomodulin has been suggested though not supported by all studies (reviewed in 1 and 15). It should be realized however that most of the observations were made in *in vitro* systems and that in the *in vitro* experiments very high levels of (free) homocysteine – up to 10 mmol/l – were used. These values differ far from the *in vivo* situation and it is questionable in our opinion whether these *in vitro* experiments represent the clinical situation. Not finding an association between mild HH and the ETP renders a direct influence of HH on plasmatic thrombin generation improbable. Therefore other factors might be relevant such as the fibrinolytic pathway, enhanced tissue factor activity, enhanced platelet aggregation, increased platelet adhesion on endothelial cells, abnormal nitrogen oxides, abnormal endothelium-derived relaxing factor and inhibition of von Willebrand factor production^{1,15}. Most of the studies supporting these hypotheses are however again limited by the high levels of homocysteine used in the *in vitro* experiments. It has also been shown that homocysteine might induce altered gene expression in endothelial cells, genes that might possibly be related to the process of thrombosis^{16,17}. Until now –to our knowledge– there is however no clear parameter observed in man that might be a clue for the pathogenetic process involved in the association of mild HH and venous thrombosis. We feel such a parameter is urgently needed to proof that the epidemiological association between HH and venous thrombosis can more likely be interpreted as a causative one. Furthermore such a parameter would be very helpful in treatment strategies for HH. Vitamins (folic acid) can easily correct HH but any antithrombotic effect of any treatment cannot be claimed yet^{12,15,18}.

References

1. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. *Blood* 1997;90:1-11.
2. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. *Circulation* 1997;95:1777-82.
3. Heijer M den, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. *Thromb Haemost* 1998;80:824-7.
4. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. *Thromb Haemost* 1993;70:617-24.
5. Hemker HC, Béguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. *Thromb Haemost* 1995;74: 134-8.
6. Wielders S, Mukheerje M, Michiels J, Rijkers DTS, Cambus J-P, Knebel RWC, Kakkar V, Hemker HC, Béguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyperand hypocoagulability. *Thromb Haemost* 1997;77:629-36.
7. Rottevel RC, Roozendaal KJ, Eijlsman L, Hemker HC. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). *Thromb Haemost* 1993;70: 959-62.
8. Nicolaes GAF, Thomassen MCLGD, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. A prothrombinase-based assay for detection of resistance to activated protein C. *Thromb Haemost* 1996;76:404-10.
9. Nicolaes GAF, Thomassen MCLGD, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. *Blood Coag Fibrinol* 1997;8:28-38.
10. Duchemin J, Pittet JL, Tortary M, Béguin S, Gaussem P, Alhenc-Gelas M, Aiach M. A new method based on thrombin generation inhibition to detect both protein C and Protein S deficiencies in plasma. *Thromb Haemost* 1994;71:331-8.
11. Rijkers DTS, Wielders SJH, Alhenc-Gelas M, Béguin S, Hemker HC. The thrombomodulin ratio: a screening test for the protein C pathway. *Thromb Haemost* 1997;77(S):2251 (Abstract).
12. Heijer M den, IA Brouwer, GMJ Bos, HJ Blom, AP Spaans, FR Rosendaal, Thomas CMG, Haak HL, Weijermans PW, Gerrits WBJ. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. *Arterioscler Thromb Vasc Biol* 1998;18:356-61.
13. Heijer M den, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? *Lancet* 1995;345: 882-5.
14. Heijer M den, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal F. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. *NEJM* 1996; 334:759-62.
15. Welch GN, Loscalzo J. Mechanisms of disease: Homocysteine and atherothrombosis. *NEJM* 1988;338:1042-50.
16. Tsai J, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, Haber E, Hung-Tse Chang T, Schlegel R, Lee M. Induction of cyclin a gene expression by homocysteine in vascular smooth muscle cells. *J Clin Invest* 1996;97:146-53.
17. Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. *J Biol Chem* 1996;271:29659-65.
18. Homocysteine Lowering Trialist Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *BMJ* 1998;316:894-8.